The Cancer Pathway Everyone Gave Up On Just Got a $108M Bet
The AKT cancer pathway has crushed more drug developer dreams than any other target in oncology. Now Terremoto Biosciences just raised $108 million to try again, armed with a new chemistry trick and a CEO who already built a $5.8 billion company.
A Graveyard Gets a New Visitor
In oncology drug development, few pathways have crushed more dreams than AKT.
For over a decade, pharmaceutical companies poured billions into drugs targeting this cancer-driving protein. Trial after trial flopped. Toxicity was rampant, efficacy was disappointing, and the few glimmers of response were never enough to justify the side effects.
The AKT pathway became biotech's version of a cursed house: everyone knew there was treasure inside, but nobody could get in without getting burned.
So when a small California company called Terremoto Biosciences just raised $108 million to take yet another shot at AKT, the natural question is: are they brave, or are they crazy?
The answer might be neither. They think every company before them was simply using the wrong key.
The Problem With a Sledgehammer
To understand why Terremoto's approach matters, you need to understand why everyone else failed.
AKT is actually a family of three closely related proteins: AKT1, AKT2, and AKT3. Think of them as three siblings who look almost identical but have very different jobs. AKT1 is the troublemaker, driving tumor growth in many cancers. AKT2, on the other hand, plays a critical role in regulating blood sugar and insulin.
Every previous AKT drug was a sledgehammer. It hit all three siblings at once. Sure, it knocked out AKT1 (the cancer driver), but it also knocked out AKT2. The result? Patients developed severe hyperglycemia, painful rashes, and debilitating diarrhea. In some trials, up to 24% of patients experienced dangerous blood sugar spikes alone.
Doctors couldn't give patients enough drug to actually kill tumors without making them miserable. It was like trying to remove a wasp nest by burning down the whole house.
Terremoto's bet is that selectivity changes everything. Their drugs use a novel chemistry trick: they covalently bind to lysine, an amino acid that lets them latch onto AKT1 specifically while leaving AKT2 and AKT3 alone. In plain English, they built a sniper rifle instead of a shotgun.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Inside the Pipeline
The company's lead candidate, TER-2013, is already in Phase 1 clinical trials for solid tumors. It targets cancers with specific genetic mutations in three genes: PIK3CA, AKT, and PTEN. These mutations are especially common in hormone receptor-positive breast cancer, where they show up in more than half of patients.
That's a massive potential market. Breast cancer is the most commonly diagnosed cancer worldwide, and HR-positive cases account for roughly 70% of all breast cancers.
In preclinical studies (lab and animal testing before human trials), TER-2013 showed potent AKT1 inhibition while sparing AKT2 and AKT3. The company reports robust tumor responses across multiple animal models, and crucially, none of the AKT2-related side effects that torpedoed earlier drugs: no hyperglycemia, no rash, no diarrhea.
Terremoto also has a second program, TER-4480, targeting a completely different disease: hereditary hemorrhagic telangiectasia (HHT). That's a rare inherited condition where blood vessels form abnormally, causing dangerous bleeding. In preclinical models, TER-4480 completely blocked the development of these malformed blood vessels. The company expects to file its application to start human trials later this year.
Two drugs, two very different diseases, one underlying biology. It's a smart portfolio strategy that hedges against the risk of any single program failing.
The Money and the Names Behind It
The $108 million Series C round, which closed on April 15, 2026, brought in a roster of investors that reads like a who's who of biotech venture capital.
New investors include RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines. Returning backers include OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.
If you've followed biotech investing for any length of time, those names carry weight. RA Capital and OrbiMed consistently rank among the most active and successful life sciences investors. Their presence signals that serious diligence has been done.
This isn't Terremoto's first big raise, either. The company pulled in $75 million in its 2022 Series A and a whopping $175 million Series B in 2023. That brings total disclosed funding to roughly $433 million. On a per-employee basis, that's an extraordinary amount of capital.
The CEO Who's Done This Before
Leadership matters in biotech, and Terremoto's is worth paying attention to.
CEO Charles Baum, M.D., Ph.D. took the reins in July 2024. His previous gig? Founding Mirati Therapeutics, an oncology company that Bristol Myers Squibb acquired for $5.8 billion in 2024. Before that, he led development of blockbuster cancer drugs at Pfizer, including Ibrance, Xalkori, and Inlyta.
The company's scientific roots trace to UCSF, where co-founders Matt Jacobson and Jack Taunton pioneered the lysine-binding chemistry that underpins Terremoto's entire platform. Taunton's resume includes co-founding Global Blood Therapeutics, Principia Biopharma, and Kezar Life Sciences. Board chairman Peter Thompson is a general partner at OrbiMed who co-founded the company in 2021.
In biotech, the team is often more important than the molecule. Terremoto's lineup is the equivalent of assembling an all-star coaching staff before the season starts.
The Competitive Landscape: One Approved Drug and a Lot of Skeptics
Terremoto isn't operating in a vacuum. AstraZeneca's capivasertib (brand name Truqap) became the first and only FDA-approved AKT inhibitor in late 2023, approved for HR-positive, HER2-negative breast cancer with specific pathway mutations.
Truqap's approval was a watershed moment. It proved that targeting AKT could actually work in patients, not just in mice. AstraZeneca is now pushing into prostate cancer after positive Phase III results showing improved progression-free survival in PTEN-deficient tumors.
But Truqap is a pan-AKT inhibitor, meaning it hits all three isoforms. It still carries side effects related to AKT2 inhibition. If Terremoto can prove that AKT1 selectivity delivers comparable (or better) tumor-killing power with meaningfully fewer side effects, that would be a genuinely differentiated product.
The broader AKT inhibitor market is projected to reach $6 billion by 2033, growing at roughly 15% annually. Analysts cite rising cancer prevalence and the shift toward personalized medicine as key drivers. There's room for more than one winner, especially if second-generation drugs are cleaner and more tolerable.
Why This Time Could Be Different
Let's be honest: "this time is different" is one of the most dangerous phrases in investing. But a few things genuinely separate Terremoto's approach from the wreckage of past AKT programs.
First, the science has matured. Researchers now understand that AKT1, not AKT2 or AKT3, is the predominant disease driver in most relevant cancers. Previous drugs failed partly because the field didn't yet appreciate how much damage AKT2 inhibition was causing.
Second, the chemistry is novel. Covalent binding to lysine is a relatively new trick in drug design. Most covalent drugs target cysteine, a much rarer amino acid. Terremoto's platform opens up targets that were previously considered undruggable.
Third, Truqap's approval changed the narrative. It proved the pathway works. Investors who were burned in 2015 now have clinical proof-of-concept from a real FDA approval. That's pulled money back to the table. The overall AKT inhibitor market was estimated at $1.5 to $2 billion in 2025, and it's growing fast.
Fourth, the team has receipts. Charles Baum built a company that sold for billions. The scientific founders have a track record of translating academic chemistry into approved medicines. That pedigree reduces (though doesn't eliminate) the risk of execution failure.
The Risks Nobody Wants to Talk About
Of course, preclinical data and Phase 1 trials are still very early. The overwhelming majority of oncology drugs that enter Phase 1 never make it to approval. Selectivity in a test tube doesn't always translate to selectivity in a human body.
There's also the question of resistance. Cancer cells are notoriously creative at finding workarounds when you block one pathway. The PI3K/AKT signaling network is especially complex, with feedback loops and crosstalk that have confounded drug developers for years.
And while $433 million sounds like a lot, oncology drug development is breathtakingly expensive. If TER-2013 shows early promise, Terremoto will almost certainly need to raise again (or find a partner) to fund the Phase 2 and Phase 3 trials required for approval.
The Bottom Line
Terremoto Biosciences is making a bold, scientifically grounded bet that the AKT pathway's troubled history was a problem of precision, not biology. They're backed by elite investors, led by a CEO who already built one multi-billion-dollar oncology company, and armed with chemistry that genuinely didn't exist a few years ago.
The early data looks promising. The market opportunity is huge. The risks are real.
But if you're going to storm a castle that's defeated every army before you, this is probably the team you'd want leading the charge.
Clinical & Regulatory4 min read
The Kidney Drug That Wasn't Supposed to Get Approved
Filspari just became the first FDA-approved treatment for FSGS, a rare kidney disease that's been without an approved therapy forever. The twist? The pivotal trial technically missed its main goal. How Travere pulled off the approval anyway is a story worth reading.
